Key result
IGF-1 plus growth hormone administered to rats 4 weeks post-MI increased cardiac output by 46% and decreased systemic vascular resistance by 21% (P < .001).
Why the study?
Does combined therapy with IGF-1 and growth hormone improve hemodynamics and left ventricular remodeling in rats with chronic heart failure post-myocardial infarction?
RCT (n=36)
randomized
Does combined therapy with IGF-1 and growth hormone improve hemodynamics and left ventricular remodeling in rats with chronic heart failure post-myocardial infarction?
In a rat model of chronic post-MI heart failure, combined IGF-1 and growth hormone therapy improved hemodynamics without significant adverse left ventricular remodeling.
Answers are grounded in this paper and cite their sources.
Hemodynamic gains without adverse remodeling in rat chronic HF; extends early-post-MI data but leaves open human translation.
BACKGROUND: Insulin-like growth factor-1 (IGF-1) appears to have favorable cardiac effects associated with left ventricular remodeling early after myocardial infarction in the rat. The present study was designed to determine whether IGF-1 combined with growth hormone would be beneficial later as well, when infarct healing and cardiac remodeling have occurred. METHODS AND RESULTS: Four weeks after coronary occlusion, 36 rats were randomized to IGF-1 (3 mg.kg-1.d-1) plus growth hormone (0.1 mg BID) or to placebo for 4 weeks. Treated rats had significant increases in body weight (22%), while the ratio of heart weight to body weight was unchanged. Under anesthesia, cardiac output (fluorescent microspheres) increased 46%, and systemic vascular resistance decreased by 21% (P < .001) in the treated group; a significant (22%) increase of the cardiac index was limited to treated rats with large myocardial infarctions. Small increases in the reduced left ventricular ejection fractions and left ventricular dP/dt(max) values with treatment were not significant. Treated rats showed a borderline (16%) increase in left ventricular end-diastolic volume (angiography), whereas the ratio of left ventricular end-diastolic volume to body weight was reduced in the treated group. CONCLUSIONS: IGF-1 plus growth hormone administered to rats with left ventricular failure starting 1 month after MI was associated with substantial body growth, decreased systemic vascular resistance, and increased cardiac output. The failing heart also underwent treatment-induced increases in left and right ventricular weights in proportion to body growth, but left ventricular remodeling was minor, and a decrease in the ratio of left ventricular end-diastolic volume to body weight reflected relatively less chamber dilation compared with controls. A significant interaction between size of the myocardial infarction and treatment was observed for several variables, and IGF-1 and growth hormone increased the cardia index (P < .035) in rats with a large myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Duerr et al. (1996) conducted an RCT in Chronic left ventricular failure post-myocardial infarction (n=36). IGF-1 plus growth hormone vs. Placebo was evaluated on Cardiac output and systemic vascular resistance (p=< .001). IGF-1 plus growth hormone administered to rats 4 weeks post-MI increased cardiac output by 46% and decreased systemic vascular resistance by 21% (P < .001).
Synapse has enriched 10 related papers. Consider them for comparative context: